GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nautilus Biotechnology Inc (NAS:NAUT) » Definitions » Gross Margin %

Nautilus Biotechnology (Nautilus Biotechnology) Gross Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nautilus Biotechnology Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Nautilus Biotechnology's Gross Profit for the three months ended in Mar. 2024 was $0.00 Mil. Nautilus Biotechnology's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Nautilus Biotechnology's Gross Margin % for the quarter that ended in Mar. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Nautilus Biotechnology's Gross Margin % or its related term are showing as below:


NAUT's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.9
* Ranked among companies with meaningful Gross Margin % only.

Nautilus Biotechnology had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Nautilus Biotechnology was 0.00% per year.


Nautilus Biotechnology Gross Margin % Historical Data

The historical data trend for Nautilus Biotechnology's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nautilus Biotechnology Gross Margin % Chart

Nautilus Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Gross Margin %
- - - -

Nautilus Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nautilus Biotechnology's Gross Margin %

For the Biotechnology subindustry, Nautilus Biotechnology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nautilus Biotechnology's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nautilus Biotechnology's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Nautilus Biotechnology's Gross Margin % falls into.



Nautilus Biotechnology Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Nautilus Biotechnology's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Nautilus Biotechnology's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Nautilus Biotechnology  (NAS:NAUT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Nautilus Biotechnology had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Nautilus Biotechnology Gross Margin % Related Terms

Thank you for viewing the detailed overview of Nautilus Biotechnology's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nautilus Biotechnology (Nautilus Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
2701 Eastlake Avenue East, Seattle, WA, USA, 98102
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
Executives
Michael Seth Altman director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Subramanian Sankar officer: Senior VP, Product Development C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Gwen E Weld officer: Chief People Officer C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Anna Mowry officer: CFO and Treasurer C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Matthew B. Murphy officer: General Counsel C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109
Sujal M Patel director, 10 percent owner, officer: CEO, President, and Secretary C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Mary E. Godwin officer: Senior VP, Operations 3101 WESTERN AVENUE, SEATTLE WA 98121
Karen Akinsanya director SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew S Mcilwain director 1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104
Benjamin A Horowitz 10 percent owner 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Marc L Andreessen 10 percent owner C/O ARNOLD & PORTER LLP, 3 EMBARCADERO CENTER 7TH FLOOR, SAN FRANCISCO CA 94111